Zentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Mol Cancer Ther. 2010 Jan;9(1):17-23. doi: 10.1158/1535-7163.MCT-09-0491. Epub 2010 Jan 6.
This meeting report on the fourth Fabisch Symposium for Cancer Research and Molecular Biology describes the aims of the international meeting, the main topics of the presentations, and the highlights of the conference. The fourth Fabisch Symposium was the second on Targeted Tumor Therapies and held from April 1-3, 2009 in Berlin, Germany. The meeting focused on noncarrier-based targeted tumor therapies and their clinical application. The world's leading experts in this field presented the state of the art on tumor-specific targeting and tumor growth inhibition, drug design and production, and the description of innovative strategies for improved delivery. The topics concentrated on immunotoxins and other targeted toxins as anticancer drugs, thus providing a specialized meeting platform not existing elsewhere for these therapeutics. Although a number of innovative approaches on the avoidance of immune responses against highly effective toxins were presented, a notable conclusion of the meeting and direction for future research is the acute need to further reduce the immunogenicity of the targeted toxins, which hampers the efficacy of this group of therapeutics in clinical studies. The meeting successfully fostered plans for further research and cooperation between different groups to hopefully achieve advanced translational and clinical studies.
本会议报告介绍了第四届 Fabisch 癌症研究和分子生物学研讨会的目标、演讲的主要议题和会议的重点。第四届 Fabisch 研讨会是第二届靶向肿瘤治疗研讨会，于 2009 年 4 月 1 日至 3 日在德国柏林举行。会议的重点是非载体靶向肿瘤治疗及其临床应用。该领域的世界领先专家介绍了肿瘤特异性靶向和肿瘤生长抑制、药物设计和生产以及改进递药的创新策略方面的最新进展。这些议题集中在免疫毒素和其他靶向毒素作为抗癌药物方面，因此为这些治疗方法提供了一个其他地方没有的专业会议平台。尽管提出了许多避免针对高效毒素的免疫反应的创新方法，但会议的一个显著结论和未来研究的方向是迫切需要进一步降低靶向毒素的免疫原性，这阻碍了这组治疗方法在临床研究中的疗效。会议成功地促进了不同小组之间进一步研究和合作的计划，有望实现先进的转化和临床研究。
